Severe pneumonia due to Legionella pneumophila: Prognostic factors, impact of delayed appropriate antimicrobial therapy

Intensive Care Medicine

Volumn 28, Issue 6, 2002, Pages 686-691

  Gacouin, A ^a   Le Tulzo, Y ^a   Lavoue, S ^a   Camus, C ^a   Hoff, J ^a   Bassen, R ^a   Arvieux, C ^a   Heurtin, C ^a   Thomas, R ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Erythromycin; Fluoroquinolones; Intensive care; Legionella pneumophila; Prognostic factors; Severe pneumonia; Spiramycin

Indexed keywords

ANTIINFECTIVE AGENT; ERYTHROMYCIN; MACROLIDE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPIRAMYCIN;

ADOLESCENT; ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DISEASE DURATION; DISEASE SEVERITY; ENDOTRACHEAL INTUBATION; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LEGIONELLA PNEUMOPHILA; LOGISTIC REGRESSION ANALYSIS; MALE; MORTALITY; PNEUMONIA; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SURVIVAL; SYMPTOM; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; APACHE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HUMANS; INTENSIVE CARE UNITS; LEGIONELLA PNEUMOPHILA; LEGIONNAIRES' DISEASE; MACROLIDES; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0036281657     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-002-1304-8     Document Type: Article

References (31)

1. Legionnaires' disease: Description of an epidemic of pneumonia
2. Antimicrobial chemotherapy for legionnaires' disease: Time for a change
3. Antimicrobial chemotherapy for legionnaires' disease: A review
4. The treatment of legionnaires' disease
5. In vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovofloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections
6. Comparative post-antibactericidal activities of pefloxacin, ciprofloxacin and ofloxacin against intracellular multiplication of Legionella pneumophila serogroup 1
7. Antibacterial effects of levofloxacin, erythromycin and rifampicin in a human monocyte system against Legionella pneumophila
8. Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin and rifampicin used singly and in combination against Legionella pneumophila
9. Role of the quinolones in the treatment of Legionellosis
10. Comparative study of Legionella pneumophila and other nosocomial-acquired pneumonias
11. Legionella pneumophila: A cause of severe community-acquired pneumonia
12. Prognostic factors of severe Legionella pneumonia requiring admission to ICU
13. Comparison of the activity of three antibiotic regimens in severe legionnaires' disease
14. Legionnaires' disease: Report of sixty-five nosocomially acquired cases and review of the literature
15. Surveillance for legionnaires' disease: Risk factors for morbidity and mortality
16. Epidemiology of Legionella pneumonia and factors associated with Legionella-related mortality at a tertiary care center
17. Role of immunosuppression in the evolution of legionnaires' disease
18. Rhabdomyolysis and bacterial pneumonia
19. Quality of care, process and outcomes in elderly patients with pneumonia
20. Severe community-acquired pneumonia: Assessment of severity criteria
21. Legionnaires' disease
22. Comparative study of the clinical presentation of Legionella pneumonia and other community-acquired pneumonias
23. Pneumonia due to Legionella pneumophila and pneumococcal pneumonia: Similarities and differences on presentation
24. Nosocomial and community-acquired Legionella pneumonia: Clinical comparative analysis
25. Delay in appropriate therapy of Legionella pneumonia associated with increased mortality
26. Efficacy of intravenous spiramycin in the treatment of severe legionnaires' disease
27. Sensitivity and resistance of Legionella pneumophila to some antibiotics and combinations of antibiotics
28. Comparative activity of ciprofloxacin, ofloxacin, levofloxacin and erythromycin against Legionella species by both microdilution and intracellular susceptibility testing in HL-60 cells
29. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp
30. The effects of single and combined antibiotics on the growth of Legionella pneumophila using time-kill studies
31. In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates ofLegionella